171964-75-3

Upstream product

• 171872-12-1 (4-methoxybenzoyl)-L-valyl-L-proline 
• 105181-49-5 (2R,3S)-3-amino-1,1,1-trifluoro-4-methyl-2-pentanol 
• 100-07-2 4-methoxy-benzoyl chloride 
• 95500-68-8 L-valyl-L-proline tert-butyl ester 
• 171872-14-3 N-(4-methoxybenzoyl)-L-valyl-L-proline tert-butyl ester 
• 171872-13-2 (4S,5R)-4-Isopropyl-2-oxo-5-trifluoromethyl-oxazolidine-3-carboxylic acid (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl ester 

Downstream Products

• 171964-73-1 (S)-1-[(S)-2-(4-methoxybenzamido)-3-methylbutyryl]-N-[(S)-2-methyl-1-(trifluoroacetyl)propyl]pyrrolidine-2-carboxamide 

Relevant academic research and scientific papers

Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase

The present invention relates to pyrrolidine derivatives, and more particularly to the compound (S)-1-?(S)-2-(4-methoxybenzamido)-3-methylbutyryl!-N-?(S)-2-methyl-1-(trifluoroacetyl)propyl!pyrrolidine-2-carboxamide, shown by formula I, and solvates thereo

Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase

This paper describes the development a series of peptidyl trifluoromethyl ketone inhibitors of human leukocyte elastase which are found to have excellent pharmacological profiles. Methods have been developed that allow for the synthesis of these inhibitor